All In Biotech

Drug Trial Radar · NCT00162474

Determinants of Warfarin Metabolism

Correlation Between Phenotypic Activity of CYP2C9 and Genetic Polymorphism in CYP2C9 and Warfarin Metabolism.

Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Sep 2003

Primary completion

Dec 2030

Study completion Dec 2030

Sponsor

Lead sponsor
Hadassah Medical OrganizationAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 13, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
Who can join
All sexes, from 20 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The anticoagulant effect of warfarin varies greatly among individuals. Some of this variability is attributed to differences in the activity of CYP2C9, the predominant enzyme involved in the metabolism of S-warfarin. The present study is designed to define the differences in warfarin metabolism among healthy individuals carrying different CYP2C9 genotypes. In addition, the study will define the correlation between the phenytoin metabolic ratio, a marker of CYP2C9 activity in vivo, and warfarin metabolism.

Conditions

  • Healthy

Interventions

  • WarfarinDrug

    Each participant may be given at least one CYP2C9 substrate from the following list: Warfarin, Phenytoin, Losartan, Flurbiprofen and Siponimod.

  • PhenytoinDrug

    Each participant may be given at least one CYP2C9 substrate from the following list: Warfarin, Phenytoin, Losartan, Flurbiprofen and Siponimod.

  • Losartan & HydrochlorothiazideDrug

    Each participant may be given at least one CYP2C9 substrate from the following list: Warfarin, Phenytoin, Losartan, Flurbiprofen and Siponimod.

  • FlurbiprofenDrug

    Each participant may be given at least one CYP2C9 substrate from the following list: Warfarin, Phenytoin, Losartan, Flurbiprofen and Siponimod.

  • SiponimodDrug

    Each participant may be given at least one CYP2C9 substrate from the following list: Warfarin, Phenytoin, Losartan, Flurbiprofen and Siponimod.

  • DicloxacillinDrug

    To explore possible effect of dicloxacillin on CYP2C9 activity, some participants will be administered single dose of warfarin and phenytoin before and after intake of dicloxacillin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Warfarin oral clearanceTime frame: 2 weeks
  2. Formation clearance of CYP2C9 mediated warfarin metabolitesTime frame: 2 weeks
  3. Phenytoin Metabolic Ratio, oral clearance of Phenytoin, Formation clearance of p-HPPH.Time frame: Up to 4 days (96 hours) post drug intake.
  4. Losartan oral clearance and the formation clearance of E3174.Time frame: Up to 48 hours post drug intake.
  5. Flurbiprofen oral clearance.Time frame: Up to 36 hours post drug intake.
  6. Siponimod oral clearance.Time frame: Up to 2 weeks following drug intake.
  7. Change in S-warfarin and phenytoin pharmacokinetic parameters.Time frame: Up to 6 weeks following the administration of the first warfarin single dose.
  8. Correlation between CYP2C9 substrate pharmacokinetics and genetic polymorphism.Time frame: For up to 5 years following drug intake.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hadassah Medical Organization

    Jerusalem, Israel · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.